Atria Investments Inc Has $367,000 Holdings in Neogen Co. (NASDAQ:NEOG)

Atria Investments Inc lessened its stake in Neogen Co. (NASDAQ:NEOG) by 6.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,258 shares of the company’s stock after selling 2,159 shares during the quarter. Atria Investments Inc’s holdings in Neogen were worth $367,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in NEOG. Oppenheimer Asset Management Inc. lifted its holdings in Neogen by 25.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 130,089 shares of the company’s stock valued at $2,187,000 after purchasing an additional 26,478 shares during the last quarter. Natixis Advisors LLC lifted its holdings in Neogen by 35.1% during the 3rd quarter. Natixis Advisors LLC now owns 96,374 shares of the company’s stock valued at $1,620,000 after purchasing an additional 25,061 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in Neogen by 44.5% during the 3rd quarter. Mutual of America Capital Management LLC now owns 388,954 shares of the company’s stock valued at $6,538,000 after purchasing an additional 119,865 shares during the last quarter. Lindenwold Advisors INC lifted its holdings in Neogen by 19.1% during the 3rd quarter. Lindenwold Advisors INC now owns 12,821 shares of the company’s stock valued at $216,000 after purchasing an additional 2,055 shares during the last quarter. Finally, Intech Investment Management LLC lifted its holdings in Neogen by 126.8% during the 3rd quarter. Intech Investment Management LLC now owns 65,944 shares of the company’s stock valued at $1,109,000 after purchasing an additional 36,871 shares during the last quarter. Institutional investors and hedge funds own 96.73% of the company’s stock.

Neogen Stock Down 1.8 %

Shares of NASDAQ NEOG opened at $9.05 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.46 and a current ratio of 3.77. Neogen Co. has a 52 week low of $9.01 and a 52 week high of $18.58. The stock has a market capitalization of $1.96 billion, a P/E ratio of -4.13 and a beta of 1.27. The stock’s fifty day moving average is $10.83 and its 200 day moving average is $13.23.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company had revenue of $231.30 million for the quarter, compared to analysts’ expectations of $227.16 million. During the same quarter last year, the business earned $0.11 earnings per share. Neogen’s revenue was up .7% on a year-over-year basis. Sell-side analysts forecast that Neogen Co. will post 0.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NEOG. Piper Sandler reissued a “neutral” rating and set a $13.00 target price (down previously from $16.50) on shares of Neogen in a report on Tuesday, January 21st. Guggenheim began coverage on Neogen in a report on Thursday, December 19th. They set a “buy” rating and a $15.00 target price for the company.

Insider Buying and Selling

In other news, CEO John Edward Adent purchased 23,035 shares of Neogen stock in a transaction dated Thursday, January 16th. The shares were bought at an average cost of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the acquisition, the chief executive officer now owns 269,164 shares in the company, valued at approximately $2,968,878.92. This trade represents a 9.36 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David H. Naemura purchased 14,800 shares of Neogen stock in a transaction dated Thursday, January 16th. The shares were purchased at an average price of $11.11 per share, for a total transaction of $164,428.00. Following the completion of the acquisition, the chief financial officer now owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their position. The disclosure for this purchase can be found here. 1.13% of the stock is owned by company insiders.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.